For the year ending 2025-12-31, VERA had $262,079K increase in cash & cash equivalents over the period. -$241,734K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -299,615 |
| Depreciation and amortization | 468 |
| Accretion of discount and amortization of premium on purchase of debt securities | -6,981 |
| Accretion of loan exit fee and amortization of loan costs, net | 1,857 |
| Reduction in the carrying amount of operating lease right-of-use assets | 1,449 |
| Stock-based compensation | 37,926 |
| Payment of vt-109 license fee | 800 |
| Prepaid expense and other current assets | 3,928 |
| Other assets | -51 |
| Accounts payable | 13,910 |
| Accrued and other liabilities | 14,442 |
| Operating lease liabilities | -1,483 |
| Net cash used in operating activities | -241,104 |
| Payment of vt-109 license fee | 800 |
| Purchase of property and equipment | 630 |
| Purchase of marketable securities | 310,446 |
| Proceeds from maturities of marketable securities | 506,162 |
| Proceeds from sale of marketable securities | 0 |
| Net cash provided by (used in) investing activities | 194,286 |
| Proceeds from exercise of stock options and employee stock purchase plan | 6,981 |
| Proceeds from refinancing under loan and security agreement, net | 23,338 |
| Payment of deferred issuance costs related to unfunded loan commitments | 3,517 |
| Proceeds from short swing settlement | 500 |
| Proceeds from borrowings, net of costs | 0 |
| Repurchase of common stock | 0 |
| Proceeds from issuance of common stock in follow-on offerings | 300,000 |
| Payment of issuance costs and underwriting fees related to follow-on offerings | 18,405 |
| Net cash provided by financing activities | 308,897 |
| Net increase in cash and cash equivalents | 262,079 |
| Cash and cash equivalents, beginning of year | 92,646 |
| Cash and cash equivalents, end of year | 354,725 |
Vera Therapeutics, Inc. (VERA)
Vera Therapeutics, Inc. (VERA)